Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy

Transcription

1 Sub. Sub. Status Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Lenalidomide - 2nd line treatment of multiple myeloma in patients who have contraindications to the use of bortezomib Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy Bortezomib - Treatment of 2nd or subsequent relapse in Refractory Mantle Cell Lymphoma, in patients not fit for 29 Approved 29 transplant 28 Approved Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy Trastuzumab Emstansine (Kadcyla) - For the treatment of HER-2 - positive locally advanced/ unresectable or metastatic 29 (Stage IV) breast cancer who previously received trastuzumab and a taxane, separately or in combination Approved Approved Bevacizumab - The 2nd line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal

2 Sub. Sub. Status 08 Approved Bevacizumab for the 1st line treatment of colorectal cancer 08 Approved 06 Approved Bevacizumab - 1st line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 25 Approved Abiraterone for chemotherapy naive patients 23 Approved Everolimus - 2nd line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy or where patient has a contra-indication to or is intolerant of VEGF targeted therapy 22 Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab Approved Approved Sorafenib - 1st line treatment of advanced hepatocellular carcinoma in patients with Child A disease Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Enzalutamide - For the treatment of castrate resistant prostate cancer Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab Approved Ruxolitinib - 1st line treatment of symptomatic splenomegaly in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. For new patients only

3 Sub. Sub. Status Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved Everolimus - 2nd line treatment of metastatic renal cell carcinoma where disease has progressed on or after treatment with VEGF-targeted therapy or where patient has a contra-indication to or is intolerant of VEGF targeted therapy Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved -03- Approved cetuximab for Metastatic Colorectal Cancer (2nd or 3rd Line in combination with Chemotherapy) Approved Enzalutamide - For the treatment of castrate resistant prostate cancer --25 Approved Sorafenib - 1st line treatment of advanced hepatocellular carcinoma in patients with Child A disease --21 Approved Bendamustine - 2nd and subsequent line treatment of mantle cell lymphoma in patients who have not received previous bendamustine -- Approved Enzalutamide - For the treatment of castrate resistant prostate cancer --17 Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab -- Approved -- Approved Cetuximab - Treatment of KRAS wild-type metastatic colorectal cancer in any indication outside of NICE TA176, in patients who have not previously received cetuximab up to progression. Approved for 1st line treatment in combination with Irinotecan Based Chemotherapy, 2nd or 3rd line in combination with chemotherapy, As 3rd or subsequent line as a Single Agent Treatment Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy

4 Sub. Sub. Status 28 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved Enzalutamide - For the treatment of castrate resistant prostate cancer 21 Approved Pomalidomide - For the treatment of refractory multiple myeloma 21 Approved 16 Approved 15 Approved 14 Approved 14 Approved Approved Bevacizumab - 2nd line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received bevacizumab. Only to be administered concurrently with chemotherapy, not as single agent maintenance therapy 10 Approved Axitinib - For 2nd line renal cell carcinoma with progression after TKI or a cytokine 03 Approved 06 Approved

5 Sub. Sub. Status 16 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 10 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved Approved Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab Approved Approved Cabazitaxel - 3rd line treatment of advanced castration resistant prostate cancer following docetaxel and abiraterone based treatment Brentuximab - Treatment of relapsed or refractory CD30+ Hodgkins Lymphoma in patients who have failed at least two prior multi - agent chemotherapy regimens and are not ASCT candidates Withdrawn Bendamustine - Treatment of relapsed multiple myeloma where other treatments are not appropriate 23-- Approved Bendamustine - 2nd or subsequent line treatment of CLL for patients whom fludarabine combination therapy is not a therapeutic option Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 23-- Approved Enzalutamide - For the treatment of castrate resistant prostate cancer Approved Cabazitaxel - 3rd line treatment of advanced castration resistant prostate cancer following docetaxel and abiraterone based treatment Axitinib - For 2nd line renal cell carcinoma with progression after TKI or a cytokine 22 Approved

6 Sub. Sub. Status 21 Approved 19 Approved 15 Approved 15 Approved 15 Approved Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 06 Approved Pomalidomide - For the treatment of refractory multiple myeloma 06 Approved Aflibercept - 2nd treatment of metastatic colorectal cancer 04 Approved Ruxolitinib - 2nd line treatment of symptomatic splenomegaly in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential throbocythaemia myelofibrosis. For new patients only 30 Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab 29 Approved 25 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 25 Approved 25 Approved Approved

7 Sub. Sub. Status 22 Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab 21 Approved Aflibercept - 2nd treatment of metastatic colorectal cancer 17 Approved 11 Approved Approved Approved 04 Approved 04 Approved 04 Approved Ruxilotinib - 1st line treatment of symptomatic splenomegaly in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. For new patients only Bosutinib - For the treatment of refractory chronic phase Chronic Myeloid Leukaemia (Refractory to Nilotinib or Dasatinib) Bosutinib - For the treatment of chronic phase Chronic Myeloid Leukaemia where there is intolerance of treatment(s) and where the following criteria are met: Approved Bevacizumab for the 1st line treatment of colorectal cancer Approved Bevacizumab - The 2nd line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal 23-- Withdrawn Bendamustine - Treatment of relapsed multiple myeloma where other treatments are not appropriate Approved Approved Bevacizumab for the 1st line treatment of colorectal cancer

8 Sub. Sub. Status Enzalutamide - For the treatment of castrate resistant prostate cancer 23-- Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 23-- Approved Bendamustine - Treatment of relapsed low grade NHL in patients unable to receive standard therapy Approved Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: Approved Aflibercept - 2nd treatment of metastatic colorectal cancer Approved Approved Approved Approved bendamustine - 1st line treatment of mantle cell lymphoma in combination with rituximab in patients unsuitable for standard first line treatment Approved Lenalidomide for the treatment of MDS associated with a deletion 5q cytogenetic abnormality Approved Cetuximab - Treatment of KRAS wild-type metastatic colorectal cancer in any indication outside of NICE TA176, in patients who have not previously received cetuximab up to progression. Approved for 1st line treatment in combination with Irinotecan Based Chemotherapy, 2nd or 3rd line in combination with chemotherapy, As 3rd or subsequent line as a

9 Sub. Sub. Status 31 Approved 26 Approved Single Agent Treatment 26 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 25 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 25 Approved 17 Approved Approved Approved 05 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 03 Approved Bevacizumab for the 1st line treatment of colorectal cancer Approved Cabazitaxel - 3rd line treatment of advanced castration resistant prostate cancer following docetaxel and abiraterone based treatment Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met:

10 Sub. Sub. Status Approved Bendamustine - 2nd or subsequent line treatment of CLL for patients whom fludarabine combination therapy is not a therapeutic option 28 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 25 Approved Bendamustine - 1st line treatment of low grade non - hodgkins lymphoma in combination with rituximab 21 Approved 18 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 17 Approved Axitinib - For 2nd line renal cell carcinoma with progression after TKI or a cytokine Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 11 Approved 31 Approved Bevacizumab for the 1st line treatment of advanced colorectal cancer, where the following criteria is met: 31 Approved 29 Approved Bevacizumab - The 2nd line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal 23 Approved

11 Sub. Sub. Status 23 Approved 16 Approved 14 Approved 10 Approved 10 Approved 10 Approved 10 Approved 08 Approved 08 Approved Approved Bevacizumab - 2nd line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received bevacizumab. Only to be administered concurrently with chemotherapy, not as single agent maintenance therapy Ruxolitinib - 2nd line treatment of symptomatic splenomegaly in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential throbocythaemia myelofibrosis. For new patients only Bevacizumab - 2nd line treatment of metastatic colorectal cancer in combination with standard chemotherapy in patients who have not previously received bevacizumab. Only to be administered concurrently with chemotherapy, not as single agent maintenance therapy Cetuximab - Treatment of KRAS wild-type metastatic colorectal cancer in any indication outside of NICE TA176, in patients who have not previously received cetuximab up to progression. Approved for 1st line treatment in combination with Irinotecan Based Chemotherapy, 2nd or 3rd line in combination with chemotherapy, As 3rd or subsequent line as a Single Agent Treatment

12 Sub. Sub. Status Approved Approved Axitinib - For 2nd line renal cell carcinoma with progression after TKI or a cytokine Approved Everolimus(Afinitor) with Examestane for Metastatic Breast Cancer